Great Point Partners LLC lessened its position in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 18.3% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,811,955 shares of the company's stock after selling 629,712 shares during the quarter. Autolus Therapeutics makes up about 3.0% of Great Point Partners LLC's portfolio, making the stock its 15th biggest position. Great Point Partners LLC owned about 1.06% of Autolus Therapeutics worth $10,207,000 at the end of the most recent reporting period.
Other institutional investors have also recently bought and sold shares of the company. Exchange Traded Concepts LLC raised its holdings in shares of Autolus Therapeutics by 9.8% in the third quarter. Exchange Traded Concepts LLC now owns 41,866 shares of the company's stock valued at $152,000 after purchasing an additional 3,740 shares during the last quarter. Wealth Effects LLC increased its stake in Autolus Therapeutics by 19.5% in the 2nd quarter. Wealth Effects LLC now owns 49,000 shares of the company's stock valued at $171,000 after buying an additional 8,000 shares during the last quarter. ProShare Advisors LLC acquired a new stake in Autolus Therapeutics in the 2nd quarter valued at $43,000. China Universal Asset Management Co. Ltd. increased its position in shares of Autolus Therapeutics by 63.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 38,393 shares of the company's stock worth $139,000 after purchasing an additional 14,959 shares during the last quarter. Finally, Daiwa Securities Group Inc. raised its stake in shares of Autolus Therapeutics by 2,659.7% during the 2nd quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company's stock worth $55,000 after purchasing an additional 15,293 shares in the last quarter. Institutional investors own 72.83% of the company's stock.
Autolus Therapeutics Trading Up 5.7 %
NASDAQ AUTL traded up $0.17 during midday trading on Wednesday, hitting $3.27. The company had a trading volume of 1,608,478 shares, compared to its average volume of 1,467,284. The firm has a 50-day moving average price of $3.75 and a 200-day moving average price of $3.93. The company has a market capitalization of $870.13 million, a PE ratio of -2.79 and a beta of 2.04. Autolus Therapeutics plc has a twelve month low of $2.69 and a twelve month high of $7.45.
Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.10). During the same quarter last year, the business earned ($0.26) earnings per share. On average, equities analysts anticipate that Autolus Therapeutics plc will post -0.94 EPS for the current year.
Wall Street Analyst Weigh In
A number of brokerages recently weighed in on AUTL. The Goldman Sachs Group upgraded shares of Autolus Therapeutics from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $7.00 to $7.60 in a report on Monday, November 18th. Needham & Company LLC reiterated a "buy" rating and set a $9.00 target price on shares of Autolus Therapeutics in a research note on Monday, November 11th. Finally, Redburn Atlantic raised Autolus Therapeutics from a "neutral" rating to a "buy" rating and set a $13.00 price objective on the stock in a report on Friday, November 15th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Autolus Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $10.15.
Check Out Our Latest Research Report on Autolus Therapeutics
Autolus Therapeutics Profile
(
Free Report)
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.
Featured Stories
Before you consider Autolus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Autolus Therapeutics wasn't on the list.
While Autolus Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
